jes-pa-mra-selection

Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA ther

SKILL.md

GitHub

Select appropriate mineralocorticoid receptor antagonist for PA treatment

STEP 1 — Gather Information

Collect gender, pregnancy status, need for potassium supplementation, history of gynecomastia, renal/hepatic function, cost/insurance coverage, and patient preference.
→ Proceed to assess potassium supplementation need.

STEP 2 — Rule In / Rule Out

If the patient requires potassium supplementation → select spironolactone (can be combined with K+ prep) and arrange K+ and creatinine monitoring; else → proceed to evaluate gynecomastia risk.
→ Proceed to assess gynecomastia concern.

STEP 3 — Classify or Stratify

If the patient is male with concern for gynecomastia → exclude spironolactone and consider eplerenone or esaxerenone; else → consider all three MRAs.
→ Proceed to final selection based on cost, adverse effect profile, and tolerability.

STEP 4 — Decide

Choose the MRA that best balances cost, adverse effect profile (e.g., esaxerenone lower gynecomastia risk but limited long-term data), and patient preferences; prescribe at starting dose (spironolactone 25 mg daily, eplerenone 2.5 mg daily, esaxerenone 1.25 mg daily) with potassium and renal monitoring.
→ Initiate selected MRA and schedule follow‑up in 1–2 weeks.

Clinical Guardrails / Mimics / Pitfalls

  • Avoid eplerenone or esaxerenone with potassium supplements due to heightened hyperkalemia risk.
  • Avoid spironolactone in pregnancy (anti‑androgen effects); consider eplerenone or esaxerenone if pregnancy is planned.
  • Monitor serum potassium and creatinine within 1–2 weeks of initiation and periodically thereafter.
  • Watch for spironolactone‑induced gynecomastia in males and menstrual irregularities in females.
  • Consider cost and insurance coverage; esaxerenone may have less long‑term outcome data than spironolactone or eplerenone.
  • In severe renal impairment, all MRAs require caution; follow dosing restrictions per label.

Concrete Clinical Example

A 62‑year‑old male with bilateral PA presents with persistent hypokalemia requiring oral potassium chloride. He has no gynecomastia concern. Because he needs potassium supplementation, spironolactone is selected (can be combined with K+ prep). Start spironolactone 25 mg daily; check potassium and creatinine in 1 week.

Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021, DOI: 10.1007/s00223-022-00903-5